A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity
Completed
Phase 3 Results N/ASummary of Purpose
This trial is a multicenter, open-label study to evaluate the safety and efficacy of GSK1358820 for treatment in post-stroke subjects with focal wrist, finger and in some cases, thumb spasticity. Qualified patients who complete GSK double-blind study 112958 will be enrolled. Subjects will receive a single treatment session of intramuscular GSK1358820 "200U or 240U (if thumb spasticity is present)". The subjects...
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 19 April 2012.
| 1 Sep 2010 | 3 Sep 2010 | 1 Dec 2011 | 1 Dec 2011 | 1 Jan 2012 | Unavailable |
| Start Date | First Received | 1st Completion | Completion | Verification | Results |
|---|
Trial Design
- Masking: Open Label
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Single Group Assignment
Contacts
- US GSK Clinical Trials Call Center
GSKClinicalSupportHD@gsk.com 877-379-3718
View Trial Locations
Recruitment
- Enrollment: 109
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 13 locations, 1 country
Principal Investigator
- GSK Clinical Trials
GlaxoSmithKline
